Omega Therapeutics, Inc. Common Stock
OMGA
OMGA was delisted on the 24th of February, 2025.
68 hedge funds and large institutions have $105M invested in Omega Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 12 increasing their positions, 21 reducing their positions, and 23 closing their positions.
31% more call options, than puts
Call options by funds: $94K | Put options by funds: $72K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
3% less funds holding
Funds holding: 70 → 68 (-2)
43% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 21
44% less capital invested
Capital invested by funds: $187M → $105M (-$82M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.38M |
| 2 |
6CM
683 Capital Management
New York
|
+$1.14M |
| 3 |
Millennium Management
New York
|
+$1.01M |
| 4 |
Squarepoint
New York
|
+$524K |
| 5 |
Jane Street
New York
|
+$503K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.48M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$1.27M |
| 3 |
Citigroup
New York
|
-$1.11M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.02M |
| 5 |
State Street
Boston,
Massachusetts
|
-$912K |
OMGA Hedge Fund Activity: Q2 2024 in Review
68 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Omega Therapeutics, Inc. Common Stock (OMGA) for Q2 2024, worth a combined $105M — down 44% from $187M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of OMGA and 21 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 12 added.
The largest buyer was Citadel Advisors, adding an estimated $2.38M. The largest seller was BlackRock, cutting an estimated $2.48M.
- 68 institutional investors held Omega Therapeutics, Inc. Common Stock (OMGA) as of Q2 2024, down from 70 in Q1 2024.
- Funds reported $105M of Omega Therapeutics, Inc. Common Stock stock for Q2 2024, down 44% quarter-over-quarter.
- 21 funds opened new Omega Therapeutics, Inc. Common Stock positions in Q2 2024 and 23 closed out, a net change of -2 holders.
- The largest Omega Therapeutics, Inc. Common Stock buyer in Q2 2024 was Citadel Advisors, an estimated $2.38M added.
- The largest Omega Therapeutics, Inc. Common Stock seller in Q2 2024 was BlackRock, an estimated $2.48M sold.
Based on aggregated 13F filings for Q2 2024.